Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.580
-0.060 (-1.29%)
At close: Jan 16, 2026, 4:00 PM EST
4.600
+0.020 (0.44%)
After-hours: Jan 16, 2026, 7:54 PM EST
Immuneering Employees
Immuneering had 66 employees as of December 31, 2024. The number of employees decreased by 2 or -2.94% compared to the previous year.
Employees
66
Change (1Y)
-2
Growth (1Y)
-2.94%
Revenue / Employee
n/a
Profits / Employee
-$946,915
Market Cap
295.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66 | -2 | -2.94% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Dec 31, 2020 | 26 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMRX News
- 10 days ago - Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data - Seeking Alpha
- 10 days ago - Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower - Benzinga
- 11 days ago - Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript - Seeking Alpha
- 11 days ago - Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - GlobeNewsWire
- 26 days ago - Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - GlobeNewsWire
- 4 weeks ago - Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - GlobeNewsWire
- 4 weeks ago - Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - GlobeNewsWire
- 7 weeks ago - Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire